NCT01004809

AVODART® Alopecia Post-marketing Surveillance (PMS)

An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and Effectiveness of AVODART® Administered in Korean Androgenetic Alopecia Patients According to the Prescribing Information

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 712 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: Male
• Age: 18 Years – 41 Years
• Healthy volunteers: Not accepted

Summary

Post-marketing surveillance(PMS) to monitor the safety and effectiveness of dutasteride in Korean androgenetic alopecia patients

Detailed description

An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and effectiveness of dutasteride administered in Korean androgenetic alopecia patients according to the prescribing information

Conditions

• Alopecia

Interventions

Type	Name	Description
DRUG	Dutasteride	Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.

Timeline

• Start date: 2010-04-29
• Primary completion: 2012-12-01
• Completion: 2012-12-21
• First posted: 2009-10-30
• Last updated: 2018-06-19

Locations

1 site across 1 country: South Korea